NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the May 2017 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.

**DEMOGRAPHICS**

Distribution of Respondent Types (n = 777)

- **Physician/Surgeon/Oncologist**: 65%
- **Nurse/Oncology Nurse or Clinical Nurse Specialist**: 14%
- **Pharmacist**: 4%
- **Physician Assistant or Nurse Practitioner**: 6%
- **Other Clinician**: 11%

Note: Percentages may not total 100 because of rounding.
Q1. Do you treat patients with breast cancer? (n=756)

- Yes: 68%
- No: 32%
Q2. In your opinion, what is necessary to change an oncologist’s prescribing practice for first-line therapy from endocrine monotherapy to doublet therapy (e.g. CDK4/6 inhibitor + endocrine therapy) in the appropriate patients? (Select all that apply)

- Recommendations in clinical practice guidelines (n=310) - 67%
- Reimbursement policies from payers (n=127) - 28%
- More evidence on the benefits of CDK4/6 inhibitor + endocrine therapy over endocrine monotherapy (n=250) - 54%
- Awareness around patient assistance services (n=71) - 15%

© National Comprehensive Cancer Network, Inc. 2017, All Rights Reserved. For Internal Organizational Use Only.
NCCN Trends Surveys, Data, and Reports are solely for internal organizational use. All NCCN Trends™ Surveys content and resulting data are owned by NCCN. Survey responses are kept anonymous to protect the privacy of survey respondents.
Q3. In which of the following instances do you use a CDK4/6 inhibitor + endocrine therapy in first line? (Select all that apply)

- Visceral crisis (n=61) 16%
- Visceral only disease (n=74) 20%
- Need for rapid response (n=117) 31%
- For patients with symptomatic disease (n=163) 43%
- Other (n=116) 31%
Q4. When discussing first-line treatment options with patients with HR+ metastatic breast cancer (MBC), in your experience, which of the following is predominantly associated with NOT recommending treatment with a CDK4/6 inhibitor with endocrine therapy? (n=339)

- Financial concerns such as coverage or co-pay issues: 32%
- Bone only metastatic disease: 15%
- De novo MBC: 9%
- Comorbidities: 26%
- Other: 8%
NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an NCCN Trends™ survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Sherry L. Ulrich, MBA
Market Insights Specialist
215.690.0291
ulrich@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.